-
Mashup Score: 2Rod Nordland: One of the Lucky Few | Neurological Surgery - 3 month(s) ago
When I first spoke to Rod Nordland about his diagnosis, I gave him the news as kindly and directly as I could. I do that with all my patients — I believe doctors should be honest as well as gentle when talking about a serious diagnosis. And Rod’s brain tumor was a glioblastoma multiforme (GBM), which is as serious as it gets, with a median survival time of about 15 months.
Source: neurosurgery.weillcornell.orgCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 21Imaging predictors of 4q12 amplified and RB1 mutated glioblastoma IDH-wildtype - Journal of Neuro-Oncology - 3 month(s) ago
Introduction Recent studies have identified that glioblastoma IDH-wildtype consists of different molecular subgroups with distinct prognoses. In order to accurately describe and classify gliomas, the Visually AcceSAble Rembrandt Images (VASARI) system was developed. The goal of this study was to evaluate the VASARI characteristics in molecular subgroups of IDH-wildtype glioblastoma. Methods A…
Source: link.springer.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 15Understanding current experimental models of glioblastoma-brain microenvironment interactions - 3 month(s) ago
Journal of Neuro-Oncology – Glioblastoma (GBM) is a common and devastating primary brain tumor, with median survival of 16–18 months after diagnosis in the setting of substantial resistance…
Source: link.springer.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 27Researchers discover early, promising glioblastoma treatment - 4 month(s) ago
A team of Michigan State University scientists has unveiled a potential game-changer in the fight against glioblastoma, the most common and currently incurable form of brain cancer.
Source: medicalxpress.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 22
Treatment failure for the lethal brain tumor glioblastoma (GBM) is attributed to intratumoral heterogeneity and tumor evolution. We utilized 3D neuron…
Source: www.sciencedirect.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 5Pyruvate kinase M2 (PKM-2) expression and prognostic significance in glioblastoma patients - 5 month(s) ago
Journal of Neuro-Oncology – Pyruvate kinase M2 (PKM2) is a key enzyme that catalyzes the irreversible and final step of glycolysis. It is closely associated with cancer development and progression….
Source: link.springer.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 35
Journal of Neuro-Oncology – The prognosis of patients ≥ 75 years suffering from glioblastoma is poor. Novel therapies are usually reserved for patients ≤ 70…
Source: link.springer.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
A first-in-human trial of an oncolytic virus shows that it is safe and seems to stimulate anti-tumour immune responses.
Source: www.nature.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 4
A first-in-human trial of an oncolytic virus shows that it is safe and seems to stimulate anti-tumour immune responses.
Source: www.nature.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 3CHCHD2 mediates glioblastoma cell proliferation, mitochondrial metabolism, hypoxia‑induced invasion and therapeutic resistance - 7 month(s) ago
Glioblastoma (GBM) is the most common and malignant primary brain tumor affecting adults and remains incurable. The mitochondrial coiled‑coil‑helix‑coiled‑coil‑helix domain‑containing protein 2 (CHCHD2) has been demonstrated to mediate mitochondrial respiration, nuclear gene expression and cell migration; however, evidence of this in GBM is lacking. In the present study, it was hypothesized that CHCHD2 may play a functional role in U87 GBM cells expressing the constitutively active epidermal growth factor receptor variant III (EGFRvIII). The amplification of the CHCHD2 gene was found to be associated with a decreased patient overall and progression‑free survival. The CHCHD2 mRNA levels were increased in high‑vs. low‑grade glioma, IDH‑wt GBMs, and in tumor vs. non‑tumor tissue. Additionally, CHCHD2 protein expression was greatest in invasive, EGFRvIII‑expressing patient‑derived samples. The CRISPR‑Cas9‑mediated knockout of CHCHD2 in EGFRvIII‑expressing U87 cells resulted in an altered m
Source: www.spandidos-publications.comCategories: General Medicine News, Latest HeadlinesTweet
Rod Norland had something on his side that not every #glioblastoma patient does: luck. Read my blog post about this amazing patient. https://t.co/7RxF61dMRh https://t.co/uNjUCBCdaD